Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study

B. Blumenstein, E. D. Crawford, J. H. Saiers, R. L. Stephens, S. E. Rivkin, C. A. Coltman

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

In a Southwest Oncology Group phase II clinical trial, 68 patients with hormone refractory carcinoma of the prostate were treated with a combination of doxorubicin, mitomycin C and 5-fluorouracil. Of the patients 11 were classified as good risk and 57 as poor risk. There were 1 complete and 10 partial remissions for a response rate of 16.2% (exact 95% confidence interval 8.4 to 27.1%). Median survival was 9 months (maximum 14) for good risk patients and 10 months (maximum 42) for poor risk patients. Toxicity was significant with leukopenia identified as dose limiting. Because of the low rate of response and significant toxicity, this regimen cannot be recommended as standard therapy for metastatic hormone refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)411-413
Number of pages3
JournalJournal of Urology
Volume150
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

Keywords

  • clinical trials
  • drug therapy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this